SIGMA HEALTHCARE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.3 AUD | +2.77% |
|
+3.59% | +29.35% |
| 25/03 | Miners, healthcare firms push Australia stocks higher | RE |
| 21/03 | Morgans Financial Downgrades Sigma Healthcare to Hold From Add; Price Target is AU$1.14 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company shows low valuation levels, with an enterprise value at 0.39 times its sales.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 30.12 and 25.3 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +29.35% | 1.3B | B- | ||
| +15.83% | 71.39B | C+ | ||
| +1.79% | 25.1B | C+ | ||
| -1.22% | 8.59B | C | ||
| +7.95% | 8.19B | B | ||
| -20.48% | 7.91B | B- | ||
| +15.26% | 4.31B | B+ | ||
| -1.24% | 3.93B | B- | ||
| -3.02% | 3.86B | B | ||
| +21.10% | 3.64B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
-
4 months Revenue revision
-
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SIG Stock
- Ratings Sigma Healthcare Limited
